BeOne Medicines price target lowered to $411 from $412 at Truist

Truist lowered the firm’s price target on BeOne Medicines (ONC) to $411 from $412 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 earnings in Biotech. Reactivity to regulatory and policy shifts across the sector continues to ease, and the firm also notes a recent pickup in deal activity, which has the potential to build momentum through the remainder of the year into mid-terms, the analyst tells investors in a research note. For the company, the firm expect commentary to focus on the FY26 guidance and its potential update as well as Brukinsa’s outlook amidst the competitive dynamics from Calquence’s AMPLIFY and Jaypirca, Truist added.